Strengthen our positioning as a specialist further developing new immunodiagnostics and molecular diagnostics products leveraging on the complete offer of automated proprietary analyzers on both technologies.


Consolidate the leading positioning in the immunodiagnostics leveraging the breadth of our CLIA product portfolio and further develop new specialty tests.
USA
Strategy | Related business development activity | |
---|---|---|
Commercial clients base |
| Beckman Coulter |
Hospitals Networks |
|
|
Physician Office Labs |
|


Europe
Strategy | Related business development activity | |
---|---|---|
Large Labs |
| |
Mid Labs |
| |
Small Labs |
|


China
Strategy | Related business development activity | |
---|---|---|
Class III Hospitals |
| |
Class II Hospitals |
| |
China Manifacturing |
|


New products launches to enlarge the menu adding to the LIAISON MDX platform (currently used to serve central hospital laboratories) a new Point of Care molecular platform.
Strategy | ||
---|---|---|
Expand offer with 5/6 new tests yearly:
|